RALA and onchocerciasis: Therefore, this study provides several layers of evidence supporting the safety and vaccine potentials of Ov-103 and Ov-RAL-2 for human protection against onchocerciasis, as well as strongly advocates for the advancement of these antigens through clinical development to help meet the high demand for urgent onchocerciasis vaccines.